Semaglutide 2.4 mg has been evaluated in over 25,000 people with obesity and overweight in the STEP (Semaglutide Treatment Effect in People with Obesity) and SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) clinical trial programs, across 14 clinical trials [36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51]
Both companies have faced FDA scrutiny
Moreover, overexpression of mucin MUC13 exacerbates TJ dysfunction through the janus kinase 1 (JAK1)/signal transducer and activator of transcription 3 (STAT3) and rho-associated coiled-coil containing protein kinase 2 (ROCK2)/mitogen-activated protein kinase (MAPK) signaling pathways, and IL-22 can activate these pathways [73]
Through the creation of patent thickets, which includes filing and being granted follow-on patents for minor modifications, these companies have already extended their patent protection far beyond the term of the original patents for these products
Anxiety symptoms may have preceded depressive status because no isolated depression symptoms were recorded in this study
